Selank vs. Semax: Nootropic Peptide Comparison Research

Overview: Two Russian Nootropic Peptides

Selank and Semax are both synthetic peptides developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Both are approved in Russia as nootropic drugs, both are administered intranasally, and both have been studied for cognitive enhancement and neuroprotection. Despite these similarities, they have distinct mechanisms and research profiles that make them complementary rather than interchangeable.

Origins and Structure

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a heptapeptide derived from the ACTH(4-10) fragment of adrenocorticotropic hormone. It was developed in the 1980s and approved in Russia for stroke, TBI, and cognitive disorders.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a heptapeptide analog of the endogenous immunomodulatory peptide tuftsin. It was developed in the 1990s and approved in Russia for anxiety disorders and cognitive impairment.

Mechanism Comparison

| Mechanism | Semax | Selank | |-----------|-------|--------| | BDNF upregulation | Strong | Moderate | | Dopamine system | Upregulates | Minimal | | Serotonin system | Upregulates | Modulates | | Enkephalin stabilization | Minimal | Strong | | GABA modulation | Minimal | Moderate | | Immune modulation | Moderate | Strong | | Anxiety reduction | Mild | Strong |

Cognitive Enhancement Research

Semax has been studied more extensively for pure cognitive enhancement. Research shows improvements in attention, working memory, and processing speed. Its BDNF-upregulating effects are particularly relevant to learning and memory consolidation. In stroke research, Semax significantly improved neurological outcomes and cognitive recovery. Animal studies show Semax enhances long-term potentiation (LTP) — the cellular mechanism of learning.

Selank also improves cognition but through a different primary pathway — by reducing anxiety-related cognitive interference rather than directly enhancing cognitive machinery. Research shows Selank improves memory consolidation, reduces cognitive fatigue, and improves attention, particularly in anxious subjects.

Anxiety Research

This is where the two peptides diverge most significantly:

Selank is a potent anxiolytic with a research profile comparable to benzodiazepines in terms of efficacy but without sedation, dependency, or cognitive impairment. Multiple Russian clinical trials show Selank reduces anxiety scores on standardized scales (Hamilton Anxiety Rating Scale) with an effect size comparable to phenazepam (a Russian benzodiazepine).

Semax has mild anxiolytic effects as a secondary property but is not primarily an anxiolytic. Its dopaminergic effects can actually increase arousal, which may be counterproductive in anxious subjects.

Neuroprotection Research

Both peptides show neuroprotective effects, but through different mechanisms:

| Condition | Semax Evidence | Selank Evidence | |-----------|---------------|----------------| | Ischemic stroke | Strong (clinical trials) | Moderate (preclinical) | | TBI | Moderate | Limited | | Neuroinflammation | Moderate | Moderate | | Oxidative stress | Moderate | Moderate |

Administration and Dosing

Both peptides are typically administered intranasally, which allows direct delivery to the CNS via the olfactory pathway:

- Semax: 0.1% or 1% solution, 2-3 drops per nostril, 1-3 times daily - Selank: 0.15% solution, 2-3 drops per nostril, 2-3 times daily

Both have short half-lives (minutes to hours) but produce effects lasting hours to days, suggesting downstream gene expression changes rather than purely receptor-mediated effects.

Research Selection Guide

| Research Goal | Recommended Peptide | |---------------|---------------------| | Pure cognitive enhancement | Semax | | Anxiety + cognition | Selank | | Stroke/TBI neuroprotection | Semax | | Immune modulation | Selank | | BDNF research | Semax (stronger effect) | | Enkephalin research | Selank | | Combination research | Both (complementary) |

Key Research Takeaways

Selank and Semax are complementary nootropic peptides with distinct primary mechanisms. Semax is the stronger cognitive enhancer and neuroprotectant; Selank is the superior anxiolytic and immunomodulator. For researchers studying anxiety-cognition interactions, the combination of both peptides provides a rich experimental toolkit. Both have meaningful clinical research bases from Russian trials, though independent replication in Western settings remains limited.